磷酸西格列汀干预糖尿病大鼠肾脏中VEGF的表达

①目的研究磷酸西格列汀（sitagliptin phosphate，SP）对糖尿病（diabetes mellitus，DM）大鼠肾脏中血管内皮生长因子（VEGF）表达的影响。②方法用50只雄性健康SD大鼠随机分为正常对照组（Normal control，NC组）、糖尿病对照组（DM组）和糖尿病sP治疗组（SP组），除NC组外，其余两组经腹腔注射链脲佐菌素（str eptozotocin，STZ剂量65mg／kg）制备糖尿病大鼠模型。成功后治疗组每日灌胃给予磷酸西格列汀10mg／（kg·d），分别采集各组大鼠3、6、8周后的尿液、血液标本，通过酶联免疫吸附法（ELISA）检测肾脏中血管内皮生长因子的表达；取一侧肾组织经HE染色，光镜下观察肾脏组织的病理变化，利用全自动生化仪检测血糖、肌酐、尿素氮及24h尿蛋白。③结果与NC组比较，造膜后大鼠的血糖、血肌酐、尿素氮、24h尿蛋白定量及肾脏组织中VEGF的表达明显升高（P〈0．01）有统计学意义；SP组血肌酐、尿素氮、24h尿蛋白定量及肾脏组织VEGF的表达与DM组比较明显降低（P〈0．01）。④结论磷酸西格列汀这类新型降糖药物对肾脏有一定的保护作用，可延缓糖尿病肾病的发展。

VEGF expression of sitagliptin phosphate intervention in kidney of diabetic rats

Objective To explore the effects of Vascular endothelial growth factor（VEGF） in the kidney of diabetic rats. Methods 50 male Sprague - Dawley rats were randomly divided into 3 groups： normal control group（ NC group） ,diabetes mellitus group （DM group）and the experimental group with sitagliptin phosphate treatment （SP group）. Except the normal control group, the other 2 groups were intraperitoneally injected by streptozotocin （Str eptozotocin, STZ dose 65mg/kg） to produce diabetic rat model. Afterwards, DM group and SP group were given daily phosphate sitaglipfin 10mg/（ kg· d）. The urine and blood specimens of the rats were collected after 3,6 and 8 weeks, then testing the expression of vascular endothelial growth factor in the kidney by enzyme - linked immunosorbent assay （ELISA） method. Collecting one side of the kidney tissue with HE staining to observe its pathological changes under the light microscope, and then testing the glucose, creatinine, urea nitrogen and 24h urine protein by automatic bio-chemical analyzer. Results Compared with NC group, the blood glucose, serum creatinine, blood urea nitrogen, 24h urinary pro- tein excretion and kidney tissue VEGF expression of rats afterwards were significantly increased （ P 〈 0.01 ） which was of statistical significance in the model. The creatinine, blood urea nitrogen, 24h urinary protein excretion and kidney tissue VEGF expression in SP group is significantly lower than that of the DM group （ P 〈 0.01 ）. Conclusion This new kind of antidiabetic drugs like sitaglip-tin phosphate has a protective effect on the kidneys, which may delay the progress of diabetic nephropathy.